Navigation Links
MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China

UNION CITY, Calif. and SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the nomination of MRX- I as its first preclinical development candidate. MRX-I is an antibacterial molecule targeting multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Simultaneously, the company expanded its operations in China to increase MicuRx' capacity in antibacterial drug discovery and development.

"Only 12 months after initial funding, we have discovered multiple drug leads and selected our first development candidate MRX-I, a promising antibacterial compound that we expect to be superior to many of the top- selling antibiotics available today," said Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "This enhanced productivity is owed in part to our hybrid business model that leverages the drug discovery capacity readily available in China and the superior management expertise in the United States."

"MRX-I and additional MicuRx pipeline leads have been identified using our proprietary drug discovery platform," commented Mike F. Gordeev, Ph.D., executive vice president and chief scientific officer of MicuRx. "We will continue to leverage this novel platform to further enhance the pharmacological properties and safety profile of clinically validated antibiotic classes, creating best-in-class antibiotics capable of addressing the growing problem of the bacterial multi-drug resistance."

MicuRx raised $10 million in 2007 with Morningside Group as the sole investor. To facilitate the development of its lead compounds and expand the research capacity, MicuRx recently moved its research and development operations in China to a new 10,000 square-foot facility in ZhangJian HighTech Park in Shanghai, China. The company intends to use this integrated state-of- art chemistry and biology facility for drug discovery and development activities to advance its next-generation antimicrobial products.

About Multi-Drug Resistance and MRSA

Modern antimicrobials (antibiotics and related pharmaceuticals) have substantially reduced the threat posed by infectious diseases and contributed to a dramatic drop in mortality rates over the past 30 years. However, due to widespread use of existing drugs in the community and hospital environment, pathogenic bacteria resistant to current antimicrobial therapies have evolved and become ubiquitous, presenting a global health threat. The World Health Organization has set forth a mandate to combat this growing problem and encouraged an urgent action of the member countries. MicuRx is addressing this need directly by developing best-in-class antimicrobials targeting multi- drug resistant bacteria.

About MicuRx Pharmaceuticals, Inc.

MicuRx is discovering and developing next-generation antibacterial and antifungal products. By applying designer modifications to validated antibiotics, MicuRx intends to improve overall pharmacological properties of antimicrobial drugs in order to overcome antibiotic resistance, increase the antibacterial spectrum, improve the dosing regimen, or reduce adverse side effects. The company has research and development facilities in San Francisco Bay Area and ZhangJiang High-Tech Park in Shanghai, China.

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
4. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced broader entry into the automotive market ... that match the pace of consumer electronics human interface ... sensors are ideal for the automotive industry and will ... Europe , Japan ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
Breaking Biology News(10 mins):